



VIVUS Announces Fourth Quarter and Full Year 2005 Financial Results Conference Call

Feb 16, 2006 /PRNewswire-FirstCall via COMTEX News Network/ -- VIVUS, Inc. (Nasdaq: VVUS), a leading specialty pharmaceutical company focused on the development and commercialization of novel therapeutics to restore sexual function in women and men, today announced that the company will host a conference call at 4:30 p.m. (EST) on Thursday, February 23, 2006 to discuss its accomplishments and financial results for the fourth quarter and full year ended December 31, 2005. Details for the conference call and related webcast are as follows:

Conference Call:

Toll free dial-in number: 877-660-0983

Conference ID number: 5317282

Webcast and Replay:

A live webcast and 30-day archive of the call can be accessed at www.vivus.com.

A telephone replay of the conference call will be available for 24 hours beginning February 23rd at approximately 7:30 p.m. (EST) by dialing 800-642-1687 domestically and entering reservation number 5317282.

About VIVUS

VIVUS Inc. is a pioneer in the research and development of proprietary products to restore sexual function for women and men. VIVUS' current product pipeline includes four investigational products in late stage clinical development. For women, VIVUS has initiated a Phase III program for Evamist™ for the alleviation of menopausal symptoms and a Phase IIb program with ALISTA™ for female sexual arousal disorder. Additionally, the company has completed Phase II development of Testosterone MDTs® for the treatment of hypoactive sexual desire disorder (HSDD). The MDTs system is a patented new-generation, transdermal drug delivery technology that delivers drugs directly through the skin.

For men, VIVUS has completed Phase II development of avanafil for erectile dysfunction. The company currently markets MUSE® (alprostadil) suppository for the treatment of erectile dysfunction in the U.S. and internationally through distributors. For more information on clinical trials and products, please visit the company's web site at www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on VIVUS' current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; reliance on sole source suppliers; limited sales and marketing efforts and dependence upon third parties; risks related to the development of innovative products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical studies discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ended December 31, 2004 and periodic reports filed with the Securities and Exchange Commission.

SOURCE VIVUS, Inc.

Timothy E. Morris, Chief Financial Officer of VIVUS, Inc., +1-650-934-5200; or Stephanie Diaz

or

Tim Brons, both of Vida Communication, +1-415-675-7400, for VIVUS, Inc.